BACKGROUND AND PURPOSE: For patients with ICH, knowing the rate of CT contrast extravasation may provide insight into the pathophysiology of hematoma expansion. This study assessed whether the PCT-derived PS can measure different rates of CT contrast extravasation for admission CTA spot signs, PCCT, PCL, and regions without extravasation in patients with ICH. MATERIALS AND METHODS: CT was performed at admission and at 24 hours for 16 patients with ICH with/without contrast extravasation seen on CTA and PCCT. PCT-PS was measured at admission. The Wilcoxon rank sum test with a Bonferroni correction was used to compare PS values from the following regions of interest: 1) spot sign lesions only (9 foci), 2) PCL lesions only (9 foci), 3) hematoma excluding extravasation, 4) regions contralateral to extravasation, 5) hematoma in patients without extravasation, and 6) an area contralateral to that in 5. Additionally, hematoma expansion was determined at 24 hours defined by NCCT. RESULTS: PS was 6.5 ± 1.60 mL · min(-1) × (100 g)(-1), 0.95 ± 0.39 mL · min(-1) × (100 g)(-1), 0.12 ± 0.39 mL · min(-1) × (100 g)(-1), 0.26 ± 0.09 mL · min(-1) × (100 g)(-1), 0.38 ± 0.26 mL · min(-1) × (100 g)(-1), and 0.09 ± 0.32 mL · min(-1) × (100 g)(-1) for the following: 1) spot sign lesions only (9 foci), 2) PCL lesions only (9 foci), 3) hematoma excluding extravasation, 4) regions contralateral to extravasation, 5) hematoma in patients without extravasation, and 6) an area contralateral to that in 5. PS values from spot sign lesions and PCL lesions were significantly different from each other and all other regions, respectively (P < .05). Hematoma volume increased from 34.1 ± 41.0 mL to 40.2 ± 46.1 mL in extravasation-positive patients and decreased from 19.8 ± 31.8 mL to 17.4 ± 27.3 mL in extravasation-negative patients. CONCLUSIONS: The PCT-PS parameter measures a higher rate of contrast extravasation for CTA spot sign lesions compared with PCL lesions and hematoma. Early extravasation was associated with hematoma expansion.
BACKGROUND AND PURPOSE: For patients with ICH, knowing the rate of CT contrast extravasation may provide insight into the pathophysiology of hematoma expansion. This study assessed whether the PCT-derived PS can measure different rates of CT contrast extravasation for admission CTA spot signs, PCCT, PCL, and regions without extravasation in patients with ICH. MATERIALS AND METHODS: CT was performed at admission and at 24 hours for 16 patients with ICH with/without contrast extravasation seen on CTA and PCCT. PCT-PS was measured at admission. The Wilcoxon rank sum test with a Bonferroni correction was used to compare PS values from the following regions of interest: 1) spot sign lesions only (9 foci), 2) PCL lesions only (9 foci), 3) hematoma excluding extravasation, 4) regions contralateral to extravasation, 5) hematoma in patients without extravasation, and 6) an area contralateral to that in 5. Additionally, hematoma expansion was determined at 24 hours defined by NCCT. RESULTS: PS was 6.5 ± 1.60 mL · min(-1) × (100 g)(-1), 0.95 ± 0.39 mL · min(-1) × (100 g)(-1), 0.12 ± 0.39 mL · min(-1) × (100 g)(-1), 0.26 ± 0.09 mL · min(-1) × (100 g)(-1), 0.38 ± 0.26 mL · min(-1) × (100 g)(-1), and 0.09 ± 0.32 mL · min(-1) × (100 g)(-1) for the following: 1) spot sign lesions only (9 foci), 2) PCL lesions only (9 foci), 3) hematoma excluding extravasation, 4) regions contralateral to extravasation, 5) hematoma in patients without extravasation, and 6) an area contralateral to that in 5. PS values from spot sign lesions and PCL lesions were significantly different from each other and all other regions, respectively (P < .05). Hematoma volume increased from 34.1 ± 41.0 mL to 40.2 ± 46.1 mL in extravasation-positive patients and decreased from 19.8 ± 31.8 mL to 17.4 ± 27.3 mL in extravasation-negative patients. CONCLUSIONS: The PCT-PS parameter measures a higher rate of contrast extravasation for CTA spot sign lesions compared with PCL lesions and hematoma. Early extravasation was associated with hematoma expansion.
Authors: J N Goldstein; L E Fazen; R Snider; K Schwab; S M Greenberg; E E Smith; M H Lev; J Rosand Journal: Neurology Date: 2007-03-20 Impact factor: 9.910
Authors: Ashraf Ederies; Andrew Demchuk; Tze Chia; David J Gladstone; Dar Dowlatshahi; Gabriel Bendavit; Kelly Wong; Sean P Symons; Richard I Aviv Journal: Stroke Date: 2009-03-12 Impact factor: 7.914
Authors: Andrew L Thompson; Jayme C Kosior; David J Gladstone; Julia J Hopyan; Sean P Symons; Francisco Romero; Imanuel Dzialowski; Jayanta Roy; Andrew M Demchuk; Richard I Aviv Journal: Can J Neurol Sci Date: 2009-07 Impact factor: 2.104
Authors: J W Dankbaar; J Hom; T Schneider; S-C Cheng; B C Lau; I van der Schaaf; S Virmani; S Pohlman; W P Dillon; M Wintermark Journal: AJNR Am J Neuroradiol Date: 2008-07-17 Impact factor: 3.825
Authors: Stephan A Mayer; Stephen M Davis; Brett E Skolnick; Nikolai C Brun; Kamilla Begtrup; Joseph P Broderick; Michael N Diringer; Thorsten Steiner Journal: Stroke Date: 2009-01-15 Impact factor: 7.914
Authors: Javier M Romero; H Bart Brouwers; Jingjing Lu; Josser E Delgado Almandoz; Hillary Kelly; Jeremy Heit; Joshua Goldstein; Jonathan Rosand; R Gilberto Gonzalez Journal: Stroke Date: 2013-09-10 Impact factor: 7.914
Authors: R I Aviv; T Huynh; Y Huang; D Ramsay; P Van Slyke; D Dumont; P Asmah; R Alkins; R Liu; K Hynynen Journal: AJNR Am J Neuroradiol Date: 2014-04-24 Impact factor: 3.825
Authors: Shoichiro Sato; Hisatomi Arima; Yoichiro Hirakawa; Emma Heeley; Candice Delcourt; Ronny Beer; Yuechun Li; Jingfen Zhang; Eric Jüettler; Jiguang Wang; Pablo M Lavados; Thompson Robinson; Richard I Lindley; John Chalmers; Craig S Anderson Journal: Neurology Date: 2014-11-05 Impact factor: 9.910
Authors: L Letourneau-Guillon; T Huynh; R Jakobovic; R Milwid; S P Symons; R I Aviv Journal: AJNR Am J Neuroradiol Date: 2012-10-18 Impact factor: 3.825